Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 3,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Clear all
Completed Phase 1 Interventional Results available

Low Dose IL-2 for Ulcerative Colitis

NCT02200445
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Interleukin-2 (aldesleukin).
Drug
Lead sponsor
Scott B. Snapper, MD PHD
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional Results available

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

NCT00763412
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions
placebo, repaglinide
Drug
Lead sponsor
Arbelaez, Ana Maria
Individual
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 28, 2026, 11:27 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease

NCT00511329
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid, Crohn Disease
Interventions
somatropin [rDNA origin] for injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional

Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation

NCT00372502
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Modified EGDT, Standard EGDT
Procedure
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Camden, New Jersey • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2009 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional

Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability

NCT06646757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
APP, CBT, HELP, PEER
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

NCT00850928
View directory record Official record
Conditions
Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 28, 2026, 11:27 AM EDT
Active, not recruiting Not applicable Interventional

A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

NCT06513507
View directory record Official record
Conditions
Rheumatoid Arthritis, Inflammatory Disease
Interventions
Cannabigerol (CBG)
Dietary Supplement
Lead sponsor
Raphael Pharma
Industry
Eligibility
25 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 2 Interventional

Open-Label Study To Evaluate the Safety and Efficacy of the Renal Assist Device In Patients With Acute Renal Failure

NCT00511407
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Renal tubule assist device
Device
Lead sponsor
RenaMed Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Birmingham, Alabama • Augusta, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361
View directory record Official record
Conditions
Sepsis
Interventions
Ketamine, Normal Saline placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Not applicable Interventional

The IBD&me Randomized Controlled Trial

NCT03695783
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Online decision aid called IBD&me, Standardized educational material
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational

Immune Indicators of Uveitis

NCT00089739
View directory record Official record
Conditions
GITR, GITR Ligand, Uveitis, Immunosuppression, Suppressor of Cytokine Secretion
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 1 Interventional

Towards Predicting the Analgesic Response to Ibuprofen Following Third-molar Extraction

NCT03893175
View directory record Official record
Conditions
Impacted Third Molar Tooth, Pain, Acute
Interventions
Ibuprofen, Acetaminophen, Placebo, Oxycodone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 2 Interventional Results available

Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury

NCT02106975
View directory record Official record
Conditions
Acute Lung Injury, Sepsis
Interventions
Ascorbic Acid, Placebo: 5% Dextrose in water
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Atlanta, Georgia • Lexington, Kentucky • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early-Onset Sepsis Surveillance Study

NCT00874367
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis, Gram-Negative Bacterial Infections, Gram-Positive Bacterial Infections
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
615 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 28, 2026, 11:27 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Recruiting Phase 2 Interventional

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT06798012
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
TAK-411
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
La Jolla, California • San Francisco, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

NCT07071519
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

NCT03893565
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GSK2831781 - Double Blind Phase, Placebo, GSK2831781 - Open Label phase
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Northridge, California • Rialto, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 28, 2026, 11:27 AM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

NCT03038711
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BMS-986166, Placebo matching BMS-986166
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 28, 2026, 11:27 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05767021
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
49
States / cities
Litchfield Park, Arizona • Sun City, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 28, 2026, 11:27 AM EDT
Completed No phase listed Observational

Cardiopulmonary Bypass and Inflammatory Response

NCT00167349
View directory record Official record
Conditions
Thoracic Surgery, Cardiopulmonary Bypass
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 28, 2026, 11:27 AM EDT
Terminated Phase 2 Interventional

VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease

NCT05688852
View directory record Official record
Conditions
Crohn Disease
Interventions
VTX958, VTX958 Placebo
Drug
Lead sponsor
Ventyx Biosciences, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Garden Grove, California • Lancaster, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 11:27 AM EDT